Merck Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Merck han disminuido a una tasa media anual de -3.8%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.7% anualmente. Los ingresos han ido creciendo a una tasa media de 8.8% al año. La rentabilidad financiera de Merck es de 6.2%, y sus márgenes netos son de 3.8%.

Información clave

-3.8%

Tasa de crecimiento de los beneficios

-3.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	8.8%
Rentabilidad financiera	6.2%
Margen neto	3.8%
Próxima actualización de resultados	30 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

Dec 25

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Merck. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:MRK Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	61,403	2,306	9,838	29,459
31 Dec 23	60,115	365	9,884	29,751
30 Sep 23	59,315	4,608	10,226	23,890
30 Jun 23	58,311	3,111	9,934	24,094
31 Mar 23	57,869	13,030	9,851	13,550
31 Dec 22	59,283	14,519	9,669	11,918
30 Sep 22	58,974	15,322	10,119	13,479
30 Jun 22	57,169	16,641	9,776	12,496
31 Mar 22	53,978	13,910	9,489	12,071
31 Dec 21	48,704	12,345	9,403	11,942
30 Sep 21	46,131	5,908	9,260	10,725
30 Jun 21	43,906	3,665	8,845	10,678
31 Mar 21	41,857	4,793	8,669	10,339
31 Dec 20	41,518	4,519	8,569	13,224
30 Sep 20	42,438	9,492	8,812	9,079
30 Jun 20	43,906	9,070	9,200	8,818
31 Mar 20	46,312	9,399	9,700	8,990
31 Dec 19	39,121	5,690	8,829	8,594
30 Sep 19	45,970	9,314	9,604	8,489
30 Jun 19	44,367	9,362	9,586	7,997
31 Mar 19	43,073	8,399	9,467	8,084
31 Dec 18	42,294	6,220	9,587	9,254
30 Sep 18	41,729	3,347	9,541	9,251
30 Jun 18	41,259	1,341	9,554	11,680
31 Mar 18	40,725	1,579	9,449	11,182
31 Dec 17	40,122	2,394	9,560	9,845
30 Sep 17	39,804	2,845	9,615	9,427
30 Jun 17	40,016	5,086	9,612	6,916
31 Mar 17	39,929	4,346	9,713	7,035
31 Dec 16	39,807	3,920	9,313	6,921
30 Sep 16	39,907	5,492	9,193	6,849
30 Jun 16	39,444	5,133	9,312	6,828
31 Mar 16	39,385	4,614	9,776	6,518
31 Dec 15	39,498	4,442	9,799	6,613
30 Sep 15	39,765	10,781	10,262	6,727
30 Jun 15	40,249	9,850	10,756	6,644
31 Mar 15	41,398	11,168	10,818	6,685
31 Dec 14	42,237	11,920	11,172	6,532
30 Sep 14	43,075	5,385	11,501	6,435
30 Jun 14	43,550	5,614	11,304	6,544
31 Mar 14	43,626	4,516	11,511	6,774
31 Dec 13	44,033	4,404	11,672	7,123
30 Sep 13	44,450	4,531	12,084	7,563
30 Jun 13	44,907	5,136	12,303	7,822

Ingresos de calidad: MRK tiene un gran one-off loss de $2.0B impacto en sus últimos 12 meses de resultados financieros a 31st March, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio(3.8%) de MRK son inferiores a los del año pasado (22.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de MRK han disminuido en un 3.8% al año en los últimos 5 años.

Acelerando crecimiento: MRK ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: MRK tuvo un crecimiento negativo de los beneficios (-82.3%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-6.8%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de MRK (6.2%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Merck Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

Insider exercised options and sold US$1.7m worth of stock

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 16%

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Third quarter dividend of US$0.77 announced

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta